Convenient prefilled insulin pen with flexible half-unit dosing approved and available in Canada
Convenient prefilled insulin pen with flexible half-unit dosing approved and available in Canada
Humalog(®) Junior KwikPen(®) is the latest innovation from Lilly for Canadians with diabetes
TORONTO, May 3, 2018 /CNW/ - Eli Lilly Canada Inc. (Lilly) is proud to announce that Humalog(®) [insulin lispro injection 100 units/mL] Junior KwikPen(® )is approved by Health Canada and now available to Canadians with diabetes. This new addition to the Lilly family of diabetes medicines offers people with type 1 or type 2 diabetes an easy-to-use option with flexible dosing. Humalog Junior KwikPen is the only prefilled, disposable, half-unit insulin pen in Canada.
"For younger people with diabetes, the concept of injecting insulin can be a lot to process and a big source of anxiety," says Dr. Joanne Lorraine, Lilly Canada's Medical Director, Diabetes. "As a company with a legacy in diabetes, we continue to play a role in simplifying the management of the disease for everyday life, and Humalog Junior KwikPen is another innovation from Lilly. It's prefilled, so there are fewer steps to learn, and the half-unit dosing increment allows for more precise adjustment of the insulin dose based upon the user's individual needs.
Humalog Junior KwikPen is lighter and shorter than other half-unit insulin pens, and it provides an option for people who prefer a prefilled pen and need precise half-unit dosing. Now, children and adults with smaller or more sensitive insulin requirements will be able to fine-tune their dose with a convenient prefilled disposable pen.
"We know that diabetes management can be stressful and this is something we hear directly from the community through our ongoing work. New options that improve functionality and make life simpler are incredibly important," says Dave Prowten, CEO at JDRF. "Adherence and achieving goals are critical, so every innovation is one step forward in improving the lives of people with diabetes."
Humalog Junior KwikPen enables finer dose adjustment (0.5-unit dose increments) for people who take smaller doses of Humalog. The design of Humalog Junior KwikPen meets or exceeds the requirements and standards for needle-based injections set by the International Organization for Standardization.
About Diabetes
Diabetes is a chronic disease that occurs when the body either cannot produce insulin or cannot properly use the insulin it produces. Approximately 3.3 million Canadians have type 1 or type 2 diabetes and this number is expected to rise to 4.8 million by 2024. Diabetes can result in a variety of serious complications, including heart attack, stroke, kidney failure, blindness, problems with erection (impotence), and amputation. Metabolic control has demonstrated reduction in the risk of microvascular complications.
About Eli Lilly Canada Inc.
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism. Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto, which eventually produced the world's first commercially-available insulin. Our work is focused on the areas of oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.
Ethan Pigott, Phone: 416-770-5843, Email: pigott_ethan@network.lilly.com
SOURCE Eli Lilly Canada Inc.
